Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Isopropyl butylone is a novel synthetic stimulant and substituted cathinone, structurally related to other beta-keto methylenedioxyamphetamines (noted by the "-ylone" suffix). Its formal chemical name is 1-(1,3-benzodioxol-5-yl)-2-(isopropylamino)butan-1-one. The compound was first identified in August 2024. It appears as an off-white crystalline material and has a molecular formula of C14H19NO3 with a molecular weight of 249.3 g/mol. While its precise pharmacological activity and potency are currently unknown, it is expected—based on structural similarity to other substituted cathinones—to act as a central nervous system stimulant with potential for psychoactive effects similar to amphetamines[1][7]. Like related compounds, it may function as a monoamine transporter inhibitor or releaser (serotonin, norepinephrine, dopamine), though this has not been directly confirmed for N-isopropyl butylone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-isopropyl butylone.